Research News and Research

RSS

Study finds increase in hospitalizations for children due to ATV-related injuries

All-Terrain Vehicles (ATVs) are associated with a significant and increasing number of hospitalizations for children in the U.S., according to a new report by the Center for Injury Research and Policy at the Johns Hopkins Bloomberg School of Public Health. Over a nine- year period (1997-2006) hospitalizations for ATV injuries increased 150 percent among youth younger than 18 years, with important demographic variations.

13 Oct 2010

Survey finds majority of people supported breast cancer awareness in past 12 months

Most people have supported breast cancer awareness within the past 12 months, according to a survey by Memolink of more than 3,500 of its members. Memolink.com is a leading online rewards program.

13 Oct 2010

Physicians anticipate new oral therapies for multiple sclerosis patients

Physicians are anticipating the arrival of new oral therapies for multiple sclerosis patients, with initial research showing very high awareness of oral candidates, particularly Novartis' Gilenya, which received FDA approval for relapsing forms of the disease in late September. The majority of neurologists expect Gilenya to be very useful as a therapy and trial of the drug is predicted to be strong, according to new research by GfK HealthCare.

13 Oct 2010

Studies examine risk factors for hospital readmission

In two studies published today in the Journal of Hospital Medicine, the risk factors for readmission to the hospital are examined based upon general medicine inpatients and those with at least two admissions in a six-month period. Alongside clinical factors such as having cancer, chronic diseases such as heart failure or lung disease, or being on high-risk medications, the studies identified other factors which increase the likelihood of a patient being readmitted which could help hospitalists focus in on these groups.

13 Oct 2010

Hospitalizations and associated costs with peripheral artery disease increase as condition progresses

Peripheral artery disease (PAD) is a progressive and costly disease, but remains under-diagnosed and under treated. While current PAD treatments are effective at clearing artery blockages in the lower leg, high recurrence rates and the subsequent need for repeat procedures are costly. Even after initial procedures to clear blockages in leg arteries, hospitalizations and associated costs in patients with peripheral artery disease increase as the condition progresses, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

13 Oct 2010

$1.5 million DOD award allows U-M scientists to pursue new application for nanoemulsion technology

The U.S. Department of Defense has awarded $1.5 million over three years to the Michigan Nanotechnology Institute for Medicine and Biological Sciences and to Ann Arbor-based NanoBio Corporation to develop and test nanoemulsions with potential to fight a wide range of wound infections, including drug-resistant forms.

13 Oct 2010

PAXX100 audio device improves quality of life of people with tinnitus

Tinnitus Laboratory today announced the results of a clinical study that shows significant improvements from the use of PAXX100, a customized audio device for tinnitus management designed for long-term reduction of tinnitus perception.

13 Oct 2010

Beta-Pro expands operations to meet increasing demand in $2 billion hepatocyte market

Beta-Pro LLC, announced today that it has expanded its operations to accommodate increasing demands from pharmaceutical drug discovery and research institutes in the $2 billion hepatocyte market. The human cellular sciences company now manages extensive laboratory facilities in the University of Virginia Research Park in Charlottesville, Virginia.

13 Oct 2010

USPTO grants HemoShear patent for human cell-based surrogate systems

HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."

13 Oct 2010

Gene Biodesign joins Roche NimbleGen Certified Service Provider Program

Roche NimbleGen announced today that Taipei-based genomic services provider Gene Biodesign Enterprises Co. has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program.

13 Oct 2010

Patients with memory impairment have intact ability to hold information in mind: Research

Researchers at the University of California, San Diego School of Medicine, led by Larry R. Squire, PhD, professor of psychiatry, psychology and neurosciences at UC San Diego and a scientist at the VA San Diego Healthcare System, report that working memory of relational information where an object is located, for example remains intact even if key brain structures like the hippocampus are damaged.

13 Oct 2010

Genmab and Lundbeck enter agreement to develop antibody therapeutics

Genmab A/S announced today an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) with H. Lundbeck A/S. Genmab will create novel human antibodies to three targets identified by Lundbeck. Lundbeck will have access to Genmab's antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms.

13 Oct 2010

Cellectis bioresearch establishes US subsidiary

Cellectis bioresearch, a specialist in genome customization and subsidiary of Cellectis, today announced that it has established a US subsidiary, Cellectis bioresearch Inc. Located at the Cambridge Innovation Center in Cambridge, Massachusetts, Cellectis bioresearch Inc. will be responsible for the US-wide promotion of Cellectis bioresearch products and services.

13 Oct 2010

Sirius collaborates with Golden Helix to advance diagnostic pipeline

Sirius Genomics, a developer of companion diagnostics, and Golden Helix, a global leader in genetic analysis solutions, announced today a collaboration under which Golden Helix will apply its expertise and technologies in SNP and copy number variant analysis and predictive modeling to advance development of Sirius' diagnostic pipeline.

13 Oct 2010

Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment

Kennedy Krieger Institute announced today the launch of a first‐of‐its‐kind, phase II clinical trial to investigate a treatment for heart disease in individuals with Duchenne muscular dystrophy (DMD).

13 Oct 2010

Global Hunger Index shows importance of addressing childhood malnutrition

The Global Hunger Index released Monday finds that many developing countries primarily in South Asia and Latin America have made significant progress in reducing hunger.

13 Oct 2010

NCI rates Abramson Cancer Center as 'exceptional'

The University of Pennsylvania's Abramson Cancer Center has been rated as "exceptional" by the National Cancer Institute (NCI) during a competitive research funding review by the government agency.

13 Oct 2010

New cancer initiative may promote rapid drug development

Greenville Hospital System University Medical Center (GHS) unveiled details of its new Institute for Translational Oncology Research, a visionary cancer initiative that will help pave the way for new breakthroughs in rapid drug development, diagnostic discovery and advanced cancer care. ITOR is part of the GHS Cancer Center, a recognized regional multi-disciplinary center.

13 Oct 2010

New evidence supports possible link between XMRV and prostate cancer

Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease. In three recent studies published in the November 15 issue of The Journal of Infectious Diseases, now available online, the evidence supports a possible link between XMRV and prostate cancer but not other links involving chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.

13 Oct 2010

USAID awards $15 million grant to Tufts University for CRSP program

Eileen T. Kennedy, DSc, Dean of the Friedman School of Nutrition Science and Policy at Tufts University announced today that the school has been awarded two grants totaling $15 million by the United States Agency for International Development (USAID). The USAID "Leader with Associates (LWA) Award" was granted to the school to serve as the Management Entity for a new Nutrition Collaborative Research Support Program (CRSP) in Africa and Asia. This is the first CRSP to be awarded by USAID in nearly 25 years.

13 Oct 2010